Patient's Management Receiving Eplerenone Therapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-09-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

On a population of patients followed by an office-based cardiologist and treated with eplerenone, the objectives of the survey are:

* To describe the characteristics of the population treated.
* To describe the methods of use of eplerenone (posology, duration of treatment, medicinal combinations).
* To describe the follow-up methods of the treatment.
* To describe the possible interruptions of the treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eplerenone in Heart Failure Treatment

NCT02344199

Heart Failure Acute Myocardial Infarction Hypertension

COMPLETED

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

NCT00082589

Heart Failure, Congestive

COMPLETED PHASE4

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

NCT05350969

Myocardial Infarction, Acute Heart Failure, Left Sided

COMPLETED PHASE2

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

NCT01176968

Myocardial Infarction

COMPLETED PHASE4

CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone

NCT00401856

Cardiomyopathy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A sample size in the region of N = 400 patients will allow this accuracy of estimation, as for this size, the half-width would be equal to 5% for a frequency of 50% corresponding to a confidence interval of maximum width. In view of the type of survey and the need for 12 months of monitoring in the context of standard practice, it may be anticipated that the drop-off rate will be about 20%. A sample size of N = 500 patients was therefore chosen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Left Ventricular Dysfunction Post Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eplerenone

Prospective Observational

Intervention Type OTHER

this is an observational study non interventional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prospective Observational

this is an observational study non interventional

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The following patients may be selected to participate in the survey:

* Those undergoing treatment with eplerenone in accordance with the MA or not, with a known start date.
* Those likely to be followed by the same physician for a minimal period of twelve months.